 The aims are to determine baseline bone mineral density BMD in kidney and kidneypancreas transplant patients who will be randomized to weekly alendronate, annual zoledronic acid infusions or placebo calcium with Vitamin D. These patients will be followed for two years with annual bone density testing as well as biochemical markers. A secondary aim is to evaluate compliance and tolerability of taking annual intravenous zoledronic acid versus weekly alendronate in the transplant recipient. 